Resistance to various chemotherapeutic agents is a major problem in success of
cancer chemotherapy. One of the primary reasons of development of multidrug
resistance (MDR) is the overexpression of ATP binding cassette (ABC) transporter
proteins. Breast cancer resistance protein (BCRP) belongs to ABC transporter family
and encoded by ABCG2 gene. BCRP is mainly expressed in MDR1 (P-glycoprotein)
lacking breast cancer cells. Overexpression of BCRP leads to efflux of
chemotherapeutic agents at higher rates, therefore, decreased levels of intracellular
drug accumulation. Despite the fact that several chemical modulators claim to restore
BCRP-mediated increased drug efflux, these modulators were shown to display
various side effects, precluding their clinical use. Therefore, to reverse BCRPmediated
MDR phenotype by a modulator with minimum cytotoxicity may increase
clinical benefits and minimize side effects.
| Identifer | oai:union.ndltd.org:METU/oai:etd.lib.metu.edu.tr:http://etd.lib.metu.edu.tr/upload/12614062/index.pdf |
| Date | 01 February 2012 |
| Creators | Urfali, Cagri |
| Contributors | Gunduz, Ufuk |
| Publisher | METU |
| Source Sets | Middle East Technical Univ. |
| Language | English |
| Detected Language | English |
| Type | M.S. Thesis |
| Format | text/pdf |
| Rights | Access forbidden for 1 year |
Page generated in 0.0019 seconds